$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-K Financial Statement

#000162828015001461 Filed on March 04, 2015

Income Statement

Concept	2013 Q4	2013 Q3	2013 Q2
Revenue	$309.0K	$158.0K	$75.00K
YoY Change	157.5%
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$310.0K
YoY Change	158.33%
Gross Profit Margin	100.32%
Selling, General & Admin	$3.000M	$2.142M	$3.641M
YoY Change	86.34%
% of Gross Profit	967.74%
Research & Development	$6.240M	$6.284M	$7.782M
YoY Change	-63.03%
% of Gross Profit	2012.9%
Depreciation & Amortization	$490.0K	$400.0K	$400.0K
YoY Change	8.89%	-55.06%
% of Gross Profit	158.06%
Operating Expenses	$9.240M	$8.426M	$11.42M
YoY Change	-50.03%
Operating Profit	-$8.930M	-$8.268M	-$11.35M
YoY Change	-51.39%
Interest Expense	-$160.0K	$351.0K	$490.0K
YoY Change	-102.13%
% of Operating Profit
Other Income/Expense, Net	-$990.0K	-$38.00K	-$4.000K
YoY Change	4850.0%
Pretax Income	-$10.08M	-$8.880M	-$11.83M
YoY Change	-7.52%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$10.08M	-$8.879M	-$11.83M
YoY Change	-7.5%
Net Earnings / Revenue	-3263.11%	-5619.62%	-15772.0%
Basic Earnings Per Share	-$53.63	-$55.90	-$75.25
Diluted Earnings Per Share	-$47.11	-$55.90	-$75.25
COMMON SHARES
Basic Shares Outstanding		228.8K shares	209.3K shares
Diluted Shares Outstanding		228.8K shares	209.3K shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.900M	$1.900M
YoY Change
Cash & Equivalents	$3.914M	$1.909M	$10.93M
Short-Term Investments
Other Short-Term Assets	$69.00K	$1.100M
YoY Change
Inventory
Prepaid Expenses	$531.0K
Receivables	$225.0K
Other Receivables
Total Short-Term Assets	$4.814M	$3.000M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$14.32M	$13.10M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.006M	$2.800M
YoY Change
Total Long-Term Assets	$17.83M	$15.90M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$4.814M	$3.000M
Total Long-Term Assets	$17.83M	$15.90M
Total Assets	$22.65M	$18.90M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.526M	$10.10M
YoY Change
Accrued Expenses	$4.161M	$4.900M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$22.90M	$8.300M
YoY Change
Total Short-Term Liabilities	$47.56M	$31.70M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$3.900M	$6.300M
YoY Change
Other Long-Term Liabilities	$4.800M	$4.700M
YoY Change
Total Long-Term Liabilities	$8.700M	$11.00M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$47.56M	$31.70M
Total Long-Term Liabilities	$8.700M	$11.00M
Total Liabilities	$56.21M	$42.60M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$195.9M
YoY Change
Common Stock	$38.33M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$157.5M	-$23.70M
YoY Change
Total Liabilities & Shareholders Equity	$22.65M	$18.90M
YoY Change

Cashflow Statement

Concept	2013 Q4	2013 Q3	2013 Q2
OPERATING ACTIVITIES
Net Income	-$10.08M	-$8.879M	-$11.83M
YoY Change	-7.5%
Depreciation, Depletion And Amortization	$490.0K	$400.0K	$400.0K
YoY Change	8.89%	-55.06%
Cash From Operating Activities	-$13.98M	-$6.470M	-$20.73M
YoY Change	-9.04%	-61.35%
INVESTING ACTIVITIES
Capital Expenditures	-$3.810M	-$350.0K	-$1.990M
YoY Change	12600.0%	66.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$3.800M	-$360.0K	-$1.990M
YoY Change	12566.67%	80.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	19.79M	-2.190M	6.730M
YoY Change	91.02%	-161.86%
NET CHANGE
Cash From Operating Activities	-13.98M	-6.470M	-20.73M
Cash From Investing Activities	-3.800M	-360.0K	-1.990M
Cash From Financing Activities	19.79M	-2.190M	6.730M
Net Change In Cash	2.010M	-9.020M	-15.99M
YoY Change	-139.88%	-32.69%
FREE CASH FLOW
Cash From Operating Activities	-$13.98M	-$6.470M	-$20.73M
Capital Expenditures	-$3.810M	-$350.0K	-$1.990M
Free Cash Flow	-$10.17M	-$6.120M	-$18.74M
YoY Change	-33.7%	-62.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23934832	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2014	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
CY2014	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
CY2014Q2	dei	Entity Public Float EntityPublicFloat	466400000	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013Q4	rvnc	Accrued Capital Expenditures AccruedCapitalExpenditures	0	USD
CY2014Q4	rvnc	Accrued Capital Expenditures AccruedCapitalExpenditures	266000	USD
CY2013Q4	rvnc	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	169000	USD
CY2014Q4	rvnc	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	322000	USD
CY2013Q4	rvnc	Accrued Construction In Progress Expenditures Not Yet Paid Current AccruedConstructionInProgressExpendituresNotYetPaidCurrent	1757000	USD
CY2014Q4	rvnc	Accrued Construction In Progress Expenditures Not Yet Paid Current AccruedConstructionInProgressExpendituresNotYetPaidCurrent	60000	USD
CY2013Q4	rvnc	Accrued Manufacturing Costs AccruedManufacturingCosts	0	USD
CY2014Q4	rvnc	Accrued Manufacturing Costs AccruedManufacturingCosts	361000	USD
CY2013Q4	rvnc	Accrued Milestone Obligations AccruedMilestoneObligations	367000	USD
CY2014Q4	rvnc	Accrued Milestone Obligations AccruedMilestoneObligations	577000	USD
CY2013Q4	rvnc	Accrued Offering Costs Current AccruedOfferingCostsCurrent	506000	USD
CY2014Q4	rvnc	Accrued Offering Costs Current AccruedOfferingCostsCurrent	0	USD
CY2014	rvnc	Adjustmentsto Additional Paidin Capital Terminationof Repurchase Rights Relatedto Vestingof Common Stock Issued Pursuantto Early Exercises AdjustmentstoAdditionalPaidinCapitalTerminationofRepurchaseRightsRelatedtoVestingofCommonStockIssuedPursuanttoEarlyExercises	58000	USD
CY2014Q4	rvnc	Annual Releaseof Restricted Cash AnnualReleaseofRestrictedCash	75000	USD
CY2014	rvnc	Cashand Cash Equivalents Operating Plan Funding Term CashandCashEquivalentsOperatingPlanFundingTerm	P12M
CY2012	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	125000	USD
CY2013	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	-743000	USD
CY2014	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	-210000	USD
CY2013Q4	rvnc	Common Stock Warrants Liability Current CommonStockWarrantsLiabilityCurrent	3358000	USD
CY2014Q4	rvnc	Common Stock Warrants Liability Current CommonStockWarrantsLiabilityCurrent	0	USD
CY2012	rvnc	Conversion Of Convertible Preferred Stock Warrant ConversionOfConvertiblePreferredStockWarrant	0	USD
CY2013	rvnc	Conversion Of Convertible Preferred Stock Warrant ConversionOfConvertiblePreferredStockWarrant	1168000	USD
CY2014	rvnc	Conversion Of Convertible Preferred Stock Warrant ConversionOfConvertiblePreferredStockWarrant	0	USD
CY2012	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	0	USD
CY2013	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	0	USD
CY2014	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	1441000	USD
CY2013Q4	rvnc	Convertible Preferred Stock Warrant Liability Noncurrent ConvertiblePreferredStockWarrantLiabilityNoncurrent	1233000	USD
CY2014Q4	rvnc	Convertible Preferred Stock Warrant Liability Noncurrent ConvertiblePreferredStockWarrantLiabilityNoncurrent	0	USD
CY2012	rvnc	Deemed Dividend Associated With Beneficial Conversion Of Convertible Preferred Stock DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock	0	USD
CY2013	rvnc	Deemed Dividend Associated With Beneficial Conversion Of Convertible Preferred Stock DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock	177000	USD
CY2014	rvnc	Deemed Dividend Associated With Beneficial Conversion Of Convertible Preferred Stock DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock	0	USD
CY2013Q4	rvnc	Deferred Initial Public Offering Costs DeferredInitialPublicOfferingCosts	2812000	USD
CY2014Q4	rvnc	Deferred Initial Public Offering Costs DeferredInitialPublicOfferingCosts	0	USD
CY2013Q4	rvnc	Deferred Tax Assets Fixedandintangibleassets DeferredTaxAssetsFixedandintangibleassets	2057000	USD
CY2014Q4	rvnc	Deferred Tax Assets Fixedandintangibleassets DeferredTaxAssetsFixedandintangibleassets	1771000	USD
CY2014Q4	rvnc	Deferred Tax Assets Tax Deferred Expense Compensationand Benefits Sharebased Compensation Cost Excludedfrom Net Operating Loss DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsSharebasedCompensationCostExcludedfromNetOperatingLoss	2100000	USD
CY2014	rvnc	Defined Benefit Plan Ageat Which Benefits Are Provided DefinedBenefitPlanAgeatWhichBenefitsAreProvided	P21Y
CY2013Q4	rvnc	Derivative Liabilities Contract Current DerivativeLiabilitiesContractCurrent	6684000	USD
CY2014	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-320000	USD
CY2012	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
CY2014Q4	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	423000	USD
CY2014Q4	rvnc	Financing Obligation Future Minimum Payments Next Twelve Months FinancingObligationFutureMinimumPaymentsNextTwelveMonths	423000	USD
CY2014Q4	rvnc	Derivative Liabilities Contract Current DerivativeLiabilitiesContractCurrent	0	USD
CY2012	rvnc	Derivative Liabilities Recognized As Result Of Settlement Agreement DerivativeLiabilitiesRecognizedAsResultOfSettlementAgreement	15268000	USD
CY2013	rvnc	Derivative Liabilities Recognized As Result Of Settlement Agreement DerivativeLiabilitiesRecognizedAsResultOfSettlementAgreement	0	USD
CY2014	rvnc	Derivative Liabilities Recognized As Result Of Settlement Agreement DerivativeLiabilitiesRecognizedAsResultOfSettlementAgreement	0	USD
CY2012	rvnc	Effective Income Tax Reconciliation Permanent Differences EffectiveIncomeTaxReconciliationPermanentDifferences	8887000	USD
CY2013	rvnc	Effective Income Tax Reconciliation Permanent Differences EffectiveIncomeTaxReconciliationPermanentDifferences	3931000	USD
CY2014	rvnc	Effective Income Tax Reconciliation Permanent Differences EffectiveIncomeTaxReconciliationPermanentDifferences	660000	USD
CY2012	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	0	USD
CY2013	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	0	USD
CY2014	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	1356000	USD
CY2012	rvnc	Fair Valueof Warrants Issued FairValueofWarrantsIssued	0	USD
CY2013	rvnc	Fair Valueof Warrants Issued FairValueofWarrantsIssued	0	USD
CY2014	rvnc	Fair Valueof Warrants Issued FairValueofWarrantsIssued	379000	USD
CY2013Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	0	USD
CY2014Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	598000	USD
CY2013Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	0	USD
CY2014Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	307000	USD
CY2014Q4	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	987000	USD
CY2014Q4	rvnc	Financing Obligation Future Minimum Payments Duein Three Years FinancingObligationFutureMinimumPaymentsDueinThreeYears	141000	USD
CY2012	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
CY2013	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
CY2014	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	-1356000	USD
CY2012	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	0	USD
CY2013	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	47000	USD
CY2013	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	9409000	USD
CY2014	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	1250000	USD
CY2012	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	300000	USD
CY2013	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	490000	USD
CY2014	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	203000	USD
CY2012	rvnc	Interest Expense On Notes Payable InterestExpenseOnNotesPayable	18830000	USD
CY2013	rvnc	Interest Expense On Notes Payable InterestExpenseOnNotesPayable	9220000	USD
CY2014	rvnc	Interest Expense On Notes Payable InterestExpenseOnNotesPayable	0	USD
CY2012	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	7427000	USD
CY2013	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	4128000	USD
CY2014	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	650000	USD
CY2012	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	0	USD
CY2013	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	0	USD
CY2014	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	6490000	USD
CY2012	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	0	USD
CY2013	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	2737000	USD
CY2013	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	453000	USD
CY2014	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	972000	USD
CY2012	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	18930000	USD
CY2014	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	981000	USD
CY2012	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	0	USD
CY2013	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	139000	USD
CY2014	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	80000	USD
CY2012	rvnc	Issuanceof Common Stock Warrants Convertible Preferred Stock Financing IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing	153000	USD
CY2013	rvnc	Issuanceof Common Stock Warrants Convertible Preferred Stock Financing IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing	4272000	USD
CY2014	rvnc	Issuanceof Common Stock Warrants Convertible Preferred Stock Financing IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing	0	USD
CY2012	rvnc	Modification Of Preferred Stock In Accordance With Settlement Agreement ModificationOfPreferredStockInAccordanceWithSettlementAgreement	3225000	USD
CY2013	rvnc	Modification Of Preferred Stock In Accordance With Settlement Agreement ModificationOfPreferredStockInAccordanceWithSettlementAgreement	0	USD
CY2014	rvnc	Modification Of Preferred Stock In Accordance With Settlement Agreement ModificationOfPreferredStockInAccordanceWithSettlementAgreement	0	USD
CY2012	rvnc	Non Cash Deferred Followon Public Offering Costs NonCashDeferredFollowonPublicOfferingCosts	0	USD
CY2013	rvnc	Non Cash Deferred Followon Public Offering Costs NonCashDeferredFollowonPublicOfferingCosts	0	USD
CY2014	rvnc	Non Cash Deferred Followon Public Offering Costs NonCashDeferredFollowonPublicOfferingCosts	546000	USD
CY2012	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	0	USD
CY2013	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	2490000	USD
CY2014	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	4028000	USD
CY2012	rvnc	Noncash Interest Expense NoncashInterestExpense	26657000	USD
CY2013	rvnc	Noncash Interest Expense NoncashInterestExpense	13574000	USD
CY2014	rvnc	Noncash Interest Expense NoncashInterestExpense	9490000	USD
CY2014Q4	rvnc	Restricted Cash Minimum Balance RestrictedCashMinimumBalance	400000	USD
CY2012	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	125000	USD
CY2013	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	425000	USD
CY2014	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	-210000	USD
CY2014Q1	rvnc	Stock Issued During Period Shares Conversionof Convertible Securities Equity StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesEquity	8689999	shares
CY2014	rvnc	Stock Issued During Period Value Conversionof Convertible Securities Debt StockIssuedDuringPeriodValueConversionofConvertibleSecuritiesDebt	26206000	USD
CY2014	rvnc	Stock Issued During Period Value Conversionof Convertible Securities Equity StockIssuedDuringPeriodValueConversionofConvertibleSecuritiesEquity	123981000	USD
CY2012	rvnc	Stock Issued During Period Value New Issues Exerciseof Common Stock Warrants StockIssuedDuringPeriodValueNewIssuesExerciseofCommonStockWarrants	1000	USD
CY2013	rvnc	Stock Issued During Period Value New Issues Exerciseof Common Stock Warrants StockIssuedDuringPeriodValueNewIssuesExerciseofCommonStockWarrants	7000	USD
CY2014	rvnc	Stock Issued During Period Value New Issues Upon Net Exerciseof Common Stock Warrantsand Related Extinguishmentof Warranty Liabilityin Connectionwith Initial Public Offering StockIssuedDuringPeriodValueNewIssuesUponNetExerciseofCommonStockWarrantsandRelatedExtinguishmentofWarrantyLiabilityinConnectionwithInitialPublicOffering	6490000	USD
CY2014	rvnc	Temporary Equity Stock Issued During Period Shares New Issues Initial Public Offering TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesInitialPublicOffering	-8689999	shares
CY2014	rvnc	Temporary Equity Stock Issued During Period Value New Issues Initial Public Offering TemporaryEquityStockIssuedDuringPeriodValueNewIssuesInitialPublicOffering	-123982000	USD
CY2014Q1	rvnc	Tenant Improvement Allowance TenantImprovementAllowance	3000000	USD
CY2012	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	0	USD
CY2013	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	0	USD
CY2014	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	58000	USD
CY2013Q1	rvnc	Weighted Average Probability Income Approach WeightedAverageProbabilityIncomeApproach	0.4
CY2013Q1	rvnc	Weighted Average Probability Market Based WeightedAverageProbabilityMarketBased	0.6
CY2014Q4	rvnc	Working Capital Surplus WorkingCapitalSurplus	162500000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5526000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3149000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	225000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	300000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4161000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4145000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8189000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9906000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38331000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	435142000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	349000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	79000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	548000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6513000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	153000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	379000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	79000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	548000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6530000	USD
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7427000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4128000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1250000	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	300000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	217000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	203000	USD
CY2013Q4	us-gaap	Assets Assets	22645000	USD
CY2014Q4	us-gaap	Assets Assets	192469000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	4814000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	172731000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29621000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4083000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3914000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171032000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25538000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-169000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	167118000	USD
CY2012Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.15
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.15
CY2012	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9837134	shares
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	606457	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	224000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	260789	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23774465	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	260789	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23774465	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2013	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	1800000	USD
CY2014	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	500000	USD
CY2012	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	123982000	USD
CY2012	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2013	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	74894000	USD
CY2014	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	12157000	USD
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2014Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2012	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1095000	USD
CY2012	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2013	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2014	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	26206000	USD
CY2014Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	6000	USD
CY2013Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2438000	USD
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3176000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3725000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	300000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	83000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2438000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	78169000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	93260000	USD
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1610000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1541000	USD
CY2012	us-gaap	Depreciation Depreciation	1777000	USD
CY2013	us-gaap	Depreciation Depreciation	1881000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5760000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2623000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	86000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1602000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1854000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2458000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85488000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	101714000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	2438000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	0	USD
CY2014	us-gaap	Depreciation Depreciation	2051000	USD
CY2013	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	50000	USD
CY2014	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000	USD
CY2014Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Liability At Fair Value DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue	7100000	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4890000	USD
CY2014Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2013	us-gaap	Dilutive Securities DilutiveSecurities	825000	USD
CY2014	us-gaap	Dilutive Securities DilutiveSecurities		USD
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-290.48
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	25.54
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-75.25
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-55.90
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-53.63
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.17
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.24
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-290.48
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	21.00
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-75.25
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-55.90
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-47.11
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.05
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.24
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	689000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2088000	USD
CY2012	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	USD
CY2013	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	32008000	USD
CY2014	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	USD
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	621000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2151000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	166038000	USD
CY2012	us-gaap	Financing Interest Expense FinancingInterestExpense	0	USD
CY2013	us-gaap	Financing Interest Expense FinancingInterestExpense	0	USD
CY2014	us-gaap	Financing Interest Expense FinancingInterestExpense	28000	USD
CY2012	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	13860000	USD
CY2013	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2660000	USD
CY2014	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	4032000	USD
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8331000	USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2014	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2012	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2013	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2014	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	3000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14465000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10522000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16226000	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19808000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	197000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17832000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-21392000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	0	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	2888000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	756000	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	51000	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	284000	USD
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	537000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3398000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	849000	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	79000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	642000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-3137000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1028000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	3193000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3399000	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2976000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3915000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2394000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10500000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	83000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-83000	USD
CY2012	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2013	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-6927000	USD
CY2014	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-7073000	USD
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-257000	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2770000	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1621000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1125000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-422000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	999000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-238000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-133000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-549000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2012	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	641275	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	167655	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2012	us-gaap	Interest Expense InterestExpense	28959000	USD
CY2013	us-gaap	Interest Expense InterestExpense	15164000	USD
CY2014	us-gaap	Interest Expense InterestExpense	10672000	USD
CY2012	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	478000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	23000	USD
CY2012	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	7000	USD
CY2013	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2000	USD
CY2014	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	44000	USD
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	273000	USD
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	271000	USD
CY2012	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2302000	USD
CY2013	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1590000	USD
CY2014	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1182000	USD
CY2012	us-gaap	Interest Paid InterestPaid	2302000	USD
CY2013	us-gaap	Interest Paid InterestPaid	1590000	USD
CY2014	us-gaap	Interest Paid InterestPaid	1182000	USD
CY2012	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	379000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P15Y
CY2013Q4	us-gaap	Liabilities Liabilities	56212000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	16100000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22645000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	192469000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47561000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10236000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2641000	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2632000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13620000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53991000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	229091000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-244000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6402000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6900000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38914000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47758000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55073000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-58259000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-21657000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-11829000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-8879000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-10083000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-52448000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-21426000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-13302000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-13977000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-14212000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-62917000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-58259000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5216000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15750000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12789000	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13987000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	258000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21426000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13302000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13977000	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14212000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62917000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-58259000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	13307000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15750000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-12789000	USD
CY2013Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13987000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1083000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21426000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13302000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13977000	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14212000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-62917000	USD
CY2012	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	2285000	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	1348000	USD
CY2012	us-gaap	Notes Assumed1 NotesAssumed1	2255000	USD
CY2013	us-gaap	Notes Assumed1 NotesAssumed1	5750000	USD
CY2014	us-gaap	Notes Assumed1 NotesAssumed1	1050000	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	2641000	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	10702000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2635000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	43903000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	38842000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	52433000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-43186000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-38225000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-52050000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	53618000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	72800000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	5070000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5578000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5394000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5222000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	32354000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4400000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4400000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5200000	USD
CY2014	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	69000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	239000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3006000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	195000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	448000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-106000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-404000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-234000	USD
CY2012	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2013	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1438000	USD
CY2013	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	132000	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9000000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	319000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6477000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6975000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	825000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1624000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	531000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1085000	USD
CY2013Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	0	USD
CY2014Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	29000	USD
CY2012	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2013	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	102672000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	131880000	USD
CY2012	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	40646000	USD
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2012	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1000	USD
CY2013	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7000	USD
CY2014	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	18170000	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	21903000	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6750000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1771000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22504000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	585000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	510000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29180000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14315000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19274000	USD
CY2014Q4	us-gaap	Purchase Obligation PurchaseObligation	15100000	USD
CY2012	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1154000	USD
CY2013	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	982000	USD
CY2014	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	228000	USD
CY2012	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3403000	USD
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7594000	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12316000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32708000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27831000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33390000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	510000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	435000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195880000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-258797000	USD
CY2013	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	200000	USD
CY2012	us-gaap	Revenues Revenues	717000	USD
CY2013Q1	us-gaap	Revenues Revenues	75000	USD
CY2013Q2	us-gaap	Revenues Revenues	75000	USD
CY2013Q3	us-gaap	Revenues Revenues	158000	USD
CY2013Q4	us-gaap	Revenues Revenues	309000	USD
CY2013	us-gaap	Revenues Revenues	617000	USD
CY2014Q1	us-gaap	Revenues Revenues	158000	USD
CY2014Q2	us-gaap	Revenues Revenues	75000	USD
CY2014Q3	us-gaap	Revenues Revenues	75000	USD
CY2014Q4	us-gaap	Revenues Revenues	75000	USD
CY2014	us-gaap	Revenues Revenues	383000	USD
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	300000	USD
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	300000	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	300000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11195000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11011000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19043000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	79000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	548000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	6530000	USD
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.55
CY2012Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.55
CY2013Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	22.50
CY2014Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	15.45
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	17000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	131335000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1422000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-155482000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-216727000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-157549000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	176369000	USD
CY2014Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0667
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	123982000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2011Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	95433000	USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	95433000	USD
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	123982000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	USD
CY2012	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2013	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	177000	USD
CY2014	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2013Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	215264000	USD
CY2014Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2013Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	145010269	shares
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8689999	shares
CY2014Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2011Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1517381	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1517381	shares
CY2013Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	8689999	shares
CY2014Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2013	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	11256000	USD
CY2013Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	194000	USD
CY2014Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	0	USD
CY2012	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2013	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	8133000	USD
CY2014	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1912000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2012000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2288000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1268000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1216000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	100000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	276000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	196000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10500000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16200000	USD
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	200560	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1029150	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19391523	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	200560	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	220220	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19391523	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Under the Company's Investment Policy, the Company limits its credit exposure by investing in highly liquid funds with high credit quality. The Company’s cash and cash equivalents are held in the United States of America. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</font></div></div>
CY2014	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">October 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 and RT002 from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and the remaining </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2014, and (iii) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of specified regulatory milestones by the Company, or Product Approval Payment. Beginning on the third anniversary of the Settlement Date, any unpaid amount will begin to accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;"> per annum.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the Proceeds Sharing Arrangement Payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2013</font><font style="font-family:inherit;font-size:10pt;">, the Proceeds Sharing Arrangement Payment derivative was remeasured to fair value. The fair value of the Proceeds Sharing Arrangement Payment derivative as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2013</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;"> was determined using an option pricing model with the following assumption: expected term of </font><font style="font-family:inherit;font-size:10pt;">0.1</font><font style="font-family:inherit;font-size:10pt;">-</font><font style="font-family:inherit;font-size:10pt;">0.5</font><font style="font-family:inherit;font-size:10pt;"> years, risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">0.01%</font><font style="font-family:inherit;font-size:10pt;"> — </font><font style="font-family:inherit;font-size:10pt;">0.10%</font><font style="font-family:inherit;font-size:10pt;"> and volatility of </font><font style="font-family:inherit;font-size:10pt;">37.00%</font><font style="font-family:inherit;font-size:10pt;"> — </font><font style="font-family:inherit;font-size:10pt;">47.50%</font><font style="font-family:inherit;font-size:10pt;">. Upon the completion of our IPO, we paid </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> in settlement of our remaining obligation for the Proceeds Sharing Arrangement Payment. At the settlement date, the derivative liability was remeasured to the fair value of the obligation due, or </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">, and the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> to remeasure the fair value of the derivative for the remaining obligation through the date of settlement, or February 13, 2014. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Product Approval Payment derivative as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2013</font><font style="font-family:inherit;font-size:10pt;"> in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> was determined by updating the estimate of the timing and probability of the related approval and a discount factor assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.25</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">0.9%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">6.0%</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.5</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.2%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in mid-2018. The Company did not make any payments under the Product Approval Payment during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the fair value measurements during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate loss and </font><font style="font-family:inherit;font-size:10pt;">$0.05 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate gain, respectively.</font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-15-001461-index-headers.html	Edgar Link	pending
0001628280-15-001461-index.html	Edgar Link	pending
0001628280-15-001461.txt	Edgar Link	pending
0001628280-15-001461-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
graph.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20141231.xml	Edgar Link	completed
rvnc-20141231.xsd	Edgar Link	pending
rvnc-20141231_cal.xml	Edgar Link	unprocessable
rvnc-20141231_def.xml	Edgar Link	unprocessable
rvnc-20141231_lab.xml	Edgar Link	unprocessable
rvnc-20141231_pre.xml	Edgar Link	unprocessable
rvnc1231201410k.htm	Edgar Link	pending
rvnc1231201410kex1025.htm	Edgar Link	pending
rvnc1231201410kex1040.htm	Edgar Link	pending
rvnc1231201410kex1042.htm	Edgar Link	pending
rvnc1231201410kex231.htm	Edgar Link	pending
rvnc1231201410kex311.htm	Edgar Link	pending
rvnc1231201410kex312.htm	Edgar Link	pending
rvnc1231201410kex321.htm	Edgar Link	pending
rvnc1231201410kex322.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2013 Q4 Form 10-K Financial Statement

#000162828015001461 Filed on March 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2013 Q4 Form 10-K Financial Statement

#000162828015001461 Filed on March 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc